Morning Buzz: Yahoo (YHOO), Twitter. (TWTR), Netflix (NFLX), Biotie Therapies (BITI), AIG (AIG), Can-Fite BioPharma (CANF)

Shares of Yahoo! Inc. (YHOO) are feeling a boost today on the back of a positive article in this weekend’s edition of Barron’s. The publication said Yahoo could gain 35% if it sells its core business. After closing last week at $29.14, Yahoo stock is up 2.61% to $29.90 today.

Twitter, Inc. (TWTR) — The social media platform suffered a temporary outage across the globe early Tuesday morning. “Some users are currently experiencing problems accessing Twitter. We are aware of the issue and are working towards a resolution,” the company said.

Twitter shares gained $1.17 to $18.15 in pre-market trading.

Shares of Netflix, Inc. (NFLX) are higher by more than 2% to $106.30 in pre-market trading on Tuesday, after falling 7.1% last week. All eyes will be on Netflix’s latest quarterly results, which are due today after the closing bell. Wall Street analysts are on average expecting the video streaming giant to post $1.83 billion in sales during Q415. This would show a 5.17% increase from the Q315 revenue of $1.74 billion and an increase of 23.65% from the same period in Q414. EPS in Q415 are expected to come in at $0.02, a decline rate of 97.22% from $0.10 per share a year earlier. Meanwhile, EarningsWhisper.com reports a whisper number of $0.03 per share.

As a quick reminder, NFLX reported Q315 EPS of $0.07, $0.01 lower than the Street’s consensus estimate. Revs came in flat yoy to $1.74 billion versus the $1.75 billion consensus.

Biotie Therapies Corp. (BITI) up nearly 90% following this morning’s announcement of deal to be acquired by Acorda Therapeutics, Inc. (ACOR) for $25.60 per ADS.

American International Group, Inc. (AIG) – Activist investor Carl Icahn has issued an open letter to AIG Board, pushing for a break-up of the insurer.

Can-Fite BioPharma Ltd. (CANF) shares spiked 18.09% to $2.35 in pre-market trading after the biotech announced that the USPTO has issued a Notice of Allowance for a patent titled, “A3 Adenosine Receptor Allosteric Modulators”.

Be the first to comment

Leave a Reply

Your email address will not be published.


*